factMR-logo.png
Friedreich’s Ataxia Drugs Market is Projected to Reach US$ 3.49 Billion by 2034 | Fact.MR Report
August 20, 2024 06:30 ET | FACT.MR
Rockville, MD , Aug. 20, 2024 (GLOBE NEWSWIRE) -- The Global Friedreich’s Ataxia Drug Market is projected at a value of US$ 1 billion in 2024, as revealed in a newly published industry analysis by...
Logo.png
Global Next-Generation Complement Therapeutics Market to Surge Significantly at a CAGR of ~15% by 2030 | DelveInsight
August 08, 2024 13:00 ET | DelveInsight Business Research LLP
New York, USA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Global Next-Generation Complement Therapeutics Market to Surge Significantly at a CAGR of ~15% by 2030 | DelveInsight The next-generation...
Logo.png
Friedreich's Ataxia Market to Grow at a Substantial Growth Rate by 2034, Examines DelveInsight | Key Companies - Retrotope, PTC Therapeutics, Minoryx Therapeutics, Biogen, Lexeo Therapeutics, Larimar Therapeutics
July 16, 2024 13:00 ET | DelveInsight Business Research LLP
New York, USA, July 16, 2024 (GLOBE NEWSWIRE) -- Friedreich's Ataxia Market to Grow at a Substantial Growth Rate by 2034, Examines DelveInsight | Key Companies - Retrotope, PTC Therapeutics, Minoryx...
22157.jpg
Global Friedreich's Ataxia Market Analysis 2023-2034: A Projected $3.39 Billion Opportunity Featuring Strategic Analysis of Reata Pharma, Pfizer, BioMarin Pharma, Retrotope, Voyager Therapeutics, and More
May 28, 2024 07:00 ET | Research and Markets
Dublin, May 28, 2024 (GLOBE NEWSWIRE) -- The "Global Friedreich's Ataxia Market" report has been added to ResearchAndMarkets.com's offering.The global Friedreich's ataxia market accounted for USD...
Logo.png
Motor Neuron Disease Clinical Trial Pipeline Appears Robust With 120+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
May 16, 2024 13:00 ET | DelveInsight Business Research LLP
New York, USA, May 16, 2024 (GLOBE NEWSWIRE) -- Motor Neuron Disease Clinical Trial Pipeline Appears Robust With 120+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight...
Logo.png
Amyotrophic Lateral Sclerosis Market to Surge Immensely by 2032, Predicts DelveInsight | Key Companies to Watch Out - Cytokinetics, Orphazyme, Orion, Biogen, AB Science, Ionis, Biohaven, MediciNova, NeuroSense
July 19, 2023 13:00 ET | DelveInsight Business Research LLP
New York, USA, July 19, 2023 (GLOBE NEWSWIRE) -- Amyotrophic Lateral Sclerosis Market to Surge Immensely by 2032, Predicts DelveInsight | Key Companies to Watch Out - Cytokinetics, Orphazyme, Orion,...
InsightAce.jpg
Anti-Aging Therapeutics Market Reach $ 2474.54 Million to 2031 with 17.5 % CAGR | Exclusive Report by InsightAce Analytic
March 08, 2023 10:31 ET | InsightAce Analytic Pvt. LTd.
Pune, March 08, 2023 (GLOBE NEWSWIRE) -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on "Global Anti-aging Therapeutics Market (Type of Molecule (Biologics and...
sphericalinsightsoptionblue.png
Global Ataxia Market Size To Grow USD 69,889.4 Million By 2030 | CAGR of 9.5%
November 28, 2022 13:30 ET | SPHERICAL INSIGHTS LLP
New York, United States , Nov. 28, 2022 (GLOBE NEWSWIRE) -- The Global Ataxia Market Size to grow from USD 30,880.5 million in 2021 to USD 69,889.4 million by 2030, at a Compound Annual Growth Rate...
BioJiva Name + Logo.jpg
BioJiva Reports Results of Pilot Phase 2 Clinical Trial of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)
September 15, 2022 07:00 ET | BioJiva, LLC
Signals of Clinical Benefit Detected in Small Phase 2 Study, Suggesting Potential to Show Statistically Significant Therapeutic Benefit in Larger, Targeted TrialConsistent Benefit vs. Placebo in...
Logo.png
Multiple Sclerosis Pipeline Insights | Clinical Trials Evaluation Report 2022 | DelveInsight
July 06, 2022 12:00 ET | DelveInsight Business Research LLP
Las Vegas, USA, July 06, 2022 (GLOBE NEWSWIRE) -- Multiple Sclerosis Pipeline Insights | Clinical Trials Evaluation Report 2022 | DelveInsight  As per DelveInsight Multiple Sclerosis pipeline...